metaEvidence - overview

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			deaths (OS)
endometrial cancer endometrial cancer
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1
	dostarlimab plus soC vs. placebo plus SoC	2
	durvalumab plus olaparib plus SoC vs. placebo plus SoC	1
	durvalumab plus SoC vs. placebo plus SoC	1
	pembrolizumab plus SoC vs. placebo plus SoC	2	-
versus Standard of Care (SoC)
	avelumab plus SoC vs. Standard of Care (SoC)	1
	pembrolizumab plus lenvatinib vs. Standard of Care (SoC)	2
endometrial cancer - (neo)adjuvant (NA) endometrial cancer - (neo)adjuvant (NA)